HER1 IHC overexpression has been reported in 13–76% of TNBC32 and is associated with worse disease-free survival.10 HER1 overexpression frequency depends strongly on the scoring methods and the antibodies used.33 In our study, we detected high HER1 expression only in 13.8% of TNBC samples by IHC with the anti-HER1 antibody clone 31G7 (Dako), which is widely used to assess HER1 expression in colorectal cancer, and the H-Score scoring method. The gene discussed is EGFR; the disease is colorectal cancer.